Join to View Full Profile
1400 S Orange AveOrlando, FL 32806
Phone+1 407-648-3800
Fax+1 407-425-5203
Dr. Landau is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Danny Landau is an oncologist serving as a medical director of hematology telehealth care for the MUSC Health University Medical Center. His role with MUSC involves building a dynamic hematology telehealth program and expanding care throughout the state of South Carolina.
Dr. Landau is also a medical director for ThymeCare. His mission with Thyme is to help educate the team on how to provide the optimal care for our cancer population. ThymeCare and Dr. Landau have a unified vision on alleviating the burden our members have to live with as they battle their disease.
Previously, Dr. Landau worked for the Orlando Health Cancer Institute. In his role there, he served in several capacities including Interim Chair, Section Chief, Lead of GU oncology, and Patient Experience Champion. He was recognized for his work there, being named a Physician Exemplar for the hospital system.
He received his medical degree from University of South Florida Morsani College of Medicine and has been in practice more than12 years. He is experienced in every aspect of medical oncology and hematology but has put a special focus on genitourinary malignances and both benign and malignant blood conditions.
He has several publications and citings. Dr. Landau has participated as a primary investigator of clinical trials that have been published in the New England Journal of Medicine, amongst other prominent journals.
Dr. Landau has also shown a passion for writing. He was written medical papers and non medical papers alike. Dr. Landau has been quoted in magazines such as Newsweek and Readers Digest.
Education & Training
Orlando HealthFellowship, Hematology and Medical Oncology, 2008 - 2011
University of South Florida MorsaniResidency, Internal Medicine, 2005 - 2008
University of South Florida College of MedicineClass of 2005
Certifications & Licensure
VA State Medical License 2025 - 2028
FL State Medical License 2006 - 2027
ND State Medical License 2024 - 2027
OH State Medical License 2023 - 2027
SC State Medical License 2023 - 2027
ME State Medical License 2023 - 2024
PA State Medical License 2023 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage Stage 1 Certification eHealth ecoSystem, MedSeek, Inc., 2013-2017
- CMS Meaningful Use Stage Stage 1 Certification Sunrise Ambulatory Care Module Set, Allscripts, 2013-2017
- CMS Meaningful Use Stage Stage 1 Certification Sunrise Acute Care, Allscripts, 2013-2017
Clinical Trials
- S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Publications & Presentations
PubMed
- 222 citationsRucaparib or Physician's Choice in Metastatic Prostate Cancer.Karim Fizazi, Josep M Piulats, M Neil Reaume, Peter Ostler, Ray McDermott
The New England Journal of Medicine. 2023-02-23 - Cases in the management of nonmetastatic castration-resistant prostate cancer: darolutamide added to leuprolide in a 73-year-old patient.Daniel Ari Landau
Clinical Advances in Hematology & Oncology. 2022-06-01 - 3 citationsSystemic causes of non-dermatologic chronic pruritus in the pediatric population and their management: An unexplored areaPooja Gurnani, Tamir Miloh, Jayanthi Chandar, Danny Landau, Fouad Hajjar
Pediatric Dermatology. 2021-09-13
Journal Articles
- https://www.hematologyandoncology.net/supplements/cases-in-the-management-of-nonmetastatic-castration-resistant-prostate-cancer-darolutamide-added-to-leuprolide-in-a-7...landau, Clinical Advances Hematology Oncology
Lectures
- Insights into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Continuing Conversations With the Speakers on Insights into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- The internet bias toward nontraditional first line prostate cancer treatments.2019 ASCO Annual Meeting - 6/1/2019
Authored Content
- With Sickle Cell Management, Treatment Has Become 'Now What?'November 2024
- I Was so Isolated in Medicine, I Couldn't Even Talk About the WeatherSeptember 2024
- You Shouldn't Choose Medicine 'Just Because'August 2024
Press Mentions
Vitamin D Supplements May Boost Breast Cancer Treatment SuccessAugust 31st, 2025
Former MTV Star Ananda Lewis Loses Her Battle with Breast Cancer After California Covid Hospital Rules Delay Life-Saving SurgeryJune 12th, 2025
Study Links Gas Stoves to Increased Cancer Risk in Adults and ChildrenMay 18th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:











